skip to main content
About us
About United Therapeutics
Leadership
History
Pioneers
Locations & Subsidiaries
Events
Contact Us
Corporate
Corporate Responsibility
Public Benefit Corporation
Corporate Giving
Research & Medicine
Our Medicines
Remodulin
®
Tyvaso
®
| Tyvaso DPI
®
Orenitram
®
Adcirca
®
Unituxin
®
End-Stage Lung Disease
LBE 360° Transplant Support Service
Science
Therapeutics Areas
Clinical Trials
Pipeline
Medical Professionals
Science and Medical Affairs
About Science and Medical Affairs
Scientific Library
Sponsorships and Grants
Investigator Sponsored Studies
Jenesis Awards Program
™
Medical Education Grants and Scientific Sponsorships
Commercial Product - Resources and Support
United Therapeutics Cares™
United for your patients
iAssist
Specialty Therapy Initiation Platform
PAH Initiative
Regional Nurse Specialist Team
Patients
Support & Resources
Support Programs
Education
PAH Support Group Meeting Requests
Safety Initiatives
Patient Organizations
Global Product Safety and Pharmacovigilance
Careers
Careers at Unither
To be a Unitherian
Search For Job
Benefits & Amenties
Diversity & Inclusion
Company Values and Policies
Equal Opportunity Employer
Recruitment Fraud Warning
Awards & Recognitions
Corporate Site
Investors
Investors
About Us
Investor Resources
Corporate Governance
Contact IR
FAQ
Investors
About Us
Investor Resources
Corporate Governance
Contact IR
FAQ
Press releases
Quick Links
SEC Filings
Events and Presentations
CORPORATE PRESENTATION
Press Releases
Corporate Responsibility
Contact IR
back
Press Releases
Select Year
Year
All Years
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
20 Feb 2001
United Therapeutics Corporation Completes Enrollment in Phase III Intermittent Claudication Study
Download pdf
05 Feb 2001
United Therapeutics Corporation Announces Submission of MAA In France
Download pdf
03 Jan 2001
United Therapeutics and Orphan Australia Sign UT-15 Distribution Agreement
Download pdf
02 Jan 2001
United Therapeutics Obtains Exclusive License to Autologous Cell-Based Gene Therapy Technology for Pulmonary Hypertension and Other Conditions
Download pdf
(Showing 505 – 508 of
508
)
1
...
35
36
37
38
39
40
41
42
43
